Bone Healing in Multiple Myeloma with Melphalan Chemotherapy

  1. LUIS H. RODRIGUEZ, M.D.;
  2. J. BARNETT FINKELSTEIN, M.D.;
  3. C. C. SHULLENBERGER, M.D.; and
  4. RAYMOND ALEXANIAN, M.D.
  1. Houston, Texas

    Abstract

    The lateral skull roentgenograms of 216 consecutive-patients with multiple myeloma were analyzed for the occurrence of bone healing after treatment with melphalan. Of 125 patients with lytic skull lesions and an evaluable treatment trial, 68 responded to chemotherapy, and 30% of these had bone repair. When it occurred, improvement of bone lesions was always recognized within 18 months after the institution of treatment but subsequent to the onset of remission, as defined by myeloma protein reduction. Progression of lytic lesions during disease relapse usually followed evidence of increased myeloma protein production. Responding patients with bone healing did not have a degree or duration of remission superior to that of responding patients without bone repair. Serial assessment of lateral skull films are useful in confirming clinical remissions and relapses in many myeloma patients and may be of particular value in those with equivocal changes in other disease manifestations.

    Article and Author Information

    • ▸From the Departments of Medicine and Diagnostic Radiology, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Tex.

    • Supported by grant CA 03195 from the U.S. Public Health Service, Washington, D.C.

    • ▸Requests for reprints should be addressed to Raymond Alexanian, M.D., The University of Texas M. D. Anderson Hospital and Tumor Institute, 6723 Bertner Ave., Houston, Tex. 77025.

      • Received July 30, 1971.
      • Accepted December 23, 1971.
    « Previous | Next Article »Table of Contents